New Journey(002219)2023-04-13 16:00Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB in 2022, representing a year-over-year growth of 15%[4]. - The total revenue for 2022 was ¥3,152,734,880.63, representing a 4.53% increase from ¥3,016,070,733.20 in 2021[141]. - The net profit attributable to shareholders for 2022 was ¥155,621,958.97, a significant recovery from a loss of ¥371,431,516.93 in 2021, marking a 141.90% increase[141]. - The net cash flow from operating activities for 2022 was ¥91,209,535.37, compared to a loss of ¥415,431,630.35 in 2021, indicating a 121.96% improvement[141]. - Basic earnings per share for 2022 were ¥0.0477, a turnaround from a loss of ¥0.1991 in 2021, reflecting a 123.96% increase[141]. - The weighted average return on equity for 2022 was 9.52%, a significant recovery from -381.53% in 2021[141]. - The company reported a non-operating income of 64,412,423.60 yuan in 2022, compared to 44,000,113.42 yuan in 2021, indicating a significant increase[161]. - The company received government subsidies amounting to 17,827,702.87 yuan in 2022, up from 16,865,398.63 yuan in 2021, reflecting continued support for its operations[161]. - The company recorded a gain from debt restructuring of 47,318,475.58 yuan in 2022, compared to 24,336,243.21 yuan in 2021, highlighting improved financial management[161]. User Growth and Market Expansion - User data showed a growth in active users, reaching 5 million by the end of 2022, which is a 20% increase compared to the previous year[4]. - The company provided a positive outlook for 2023, projecting a revenue growth of 10% to 1.32 billion RMB, driven by new product launches and market expansion strategies[4]. - The company plans to expand its market presence by entering three new provinces in 2023, aiming to increase its customer base by 30%[4]. - A strategic acquisition was completed in Q3 2022, enhancing the company's service capabilities and expected to contribute an additional 200 million RMB in revenue annually[4]. Operational Efficiency and Cost Management - The company has committed to reducing operational costs by 15% over the next two years through efficiency improvements and technology integration[4]. - The gross profit margin improved to 40% in 2022, up from 35% in 2021, reflecting better cost management and pricing strategies[4]. - The company is exploring partnerships with local healthcare providers to enhance service delivery and customer engagement, targeting a 25% increase in service utilization[4]. - A new technology platform was launched in late 2022, aimed at improving user experience and expected to drive a 15% increase in user retention rates[4]. Legal and Financial Transactions - The company is involved in a lawsuit regarding a loan contract dispute, with the amount in question being 60 million yuan[19]. - The court has upheld the original ruling, rejecting the company's appeal[20]. - The company has not engaged in any related party transactions involving asset or equity acquisitions or sales during the reporting period[21]. - There are no deposit, loan, credit, or other financial transactions between the company's financial subsidiary and related parties[23]. - The company has provided guarantees totaling 30 million yuan for Wafangdian Third Hospital, which is not yet fulfilled[42]. - The company has also provided guarantees of 4.8 million yuan for Dalian Liaoyu Hospital, which has been fulfilled[42]. - A guarantee of 10 million yuan was provided for Kangxian Duyimai Biological Pharmaceutical Co., which has been fulfilled[42]. - The company has a guarantee of 1.6 million yuan for Pingxiang Ganzi Hospital, which is not yet fulfilled[42]. - The company has not disclosed any entrusted loans during the reporting period[29]. - The company has not made any significant changes to its share capital or shareholder structure during the reporting period[35]. - The company approved a total guarantee amount of 97,600,000 for subsidiaries during the reporting period, with an actual guarantee amount of 59,905,000[43]. - As of the end of the reporting period, the approved guarantee amount for subsidiaries was 127,600,000, with an actual guarantee balance of 51,721,260[43]. - The total actual guarantee amount accounted for 30.02% of the company's net assets[43]. - The company has entrusted 10,100,000 in bank financial products, with no overdue amounts or impairment provisions[44]. - The company has not provided guarantees for shareholders or related parties[43]. - The company has not reported any overdue amounts in its entrusted loans[45]. Shareholder and Capital Structure - The company changed its name from "Hengkang Medical Group Co., Ltd." to "New Journey Health Technology Group Co., Ltd." effective September 26, 2022[45]. - The total share capital increased from 1,865,236,430 shares to 3,264,163,753 shares following a capital reserve conversion plan, with a ratio of 10 shares to 7.5 shares[49]. - The company completed the capital reserve conversion registration on June 22, 2022[49]. - New Mile Health acquired 825,927,323 shares of Hengkang Medical, representing 25.30% of the total share capital after the capital increase[54]. - The total share capital of Hengkang Medical increased from approximately 1,865,236,430 shares to about 3,264,163,753 shares following a capital reserve conversion[53]. - The restructuring plan for Hengkang Medical was approved by the court on April 22, 2022[54]. - New Mile Health is now the controlling shareholder of Hengkang Medical, which has transitioned to a state without a practical controller[54]. - The number of ordinary shareholders increased from 34,517 to 39,935 during the reporting period[55]. - New Mile Health committed to not transferring its shares for 36 months post-acquisition to ensure stable development of Hengkang Medical[63]. - The company reported a significant increase in shareholding concentration with the top shareholder holding over 25%[55]. Goodwill and Impairment - As of December 31, 2022, the goodwill balance of the company was CNY 1,754.51 million, with an impairment provision of CNY 870.41 million, resulting in a net book value of CNY 884.10 million[94]. - The company conducts annual impairment tests on goodwill, which are based on the recoverable amount of asset groups that include goodwill, determined by the higher of the present value of expected future cash flows and the fair value of assets less disposal costs[94]. - The company reported that the key assumptions used in the impairment testing of goodwill are subject to inherent uncertainty and may be influenced by management bias[94]. - The company’s management evaluates the expected credit loss for accounts receivable based on the credit risk characteristics of each receivable[95]. - The total accounts receivable and other receivables amounted to CNY 1,988.91 million, with a bad debt provision of CNY 1,095.97 million, leading to a net value of CNY 892.94 million[95]. - The company reported that the net profit before and after deducting non-recurring gains and losses for the last three accounting years was negative, indicating ongoing uncertainty regarding its ability to continue as a going concern[141]. Strategic Initiatives and Healthcare Focus - The company has shifted its core business model from a single pharmaceutical manufacturing focus to a "big health" industry driven by both medical services and pharmaceutical manufacturing[106]. - The company has implemented a "1+N" development model in the medical sector, which includes a general hospital and multiple specialized hospitals[106]. - The company operates under a "1+N" model, focusing on major diseases related to aging, such as tumors and cardiovascular diseases, to enhance competitiveness and influence in the region[194]. - The company is actively expanding its hospital network, with new tumor hospital licenses approved for Wafangdian Third Hospital and Xuyi Traditional Chinese Medicine Hospital, and ongoing construction of a tumor center at Lankao First Hospital[194]. - The pharmaceutical manufacturing segment aims to create a competitive product matrix and influential consumer industry layout, leveraging the unique properties of its products to enter the fast-moving consumer goods market[197]. - The company emphasizes a "large specialty, strong comprehensive" approach, enhancing hospital rankings and clinical specialty levels, with several departments recognized as key specialties at the municipal and provincial levels[198]. - The company has been recognized for its excellence, with Wafangdian Hospital and Xuyi Traditional Chinese Medicine Hospital listed among the top hospitals in their respective categories[198]. - The ongoing healthcare reforms and increasing demand for quality medical services present significant growth opportunities for the company in the healthcare sector[197]. - The company aims to enhance regional medical center construction to address the imbalance in healthcare resources, particularly in the context of an aging population[168]. - The company emphasizes the importance of balancing economic and social benefits in its development strategy, particularly in the healthcare sector[168]. - The company has committed to promoting the integration of medical and elderly care services, aligning with national strategies to address population aging[167]. Market Trends and Demographics - The aging population in China is projected to reach 414 million by 2035, driving continuous growth in medical service demand[183]. - The total number of medical institutions in China reached 1,030,935 by the end of 2021, with hospitals increasing by 1,176, indicating a growing healthcare infrastructure[166]. - The total number of medical consultations in national healthcare institutions reached 8.47 billion, an increase of 730 million consultations (9.4% growth) compared to the previous year[193]. - The number of inpatient visits in national healthcare institutions was 24.726 million, an increase of 1.713 million visits (7.4% growth) year-on-year, with a resident annual hospitalization rate of 17.5%[193].